2019 PHA PH Professional Network (PHPN) Symposium Abstracts

Basic Science

Diagnosis, Screening and Assessment

1001 – Risk assessment tools in pulmonary arterial hypertension (PAH): A survey of real-world practices and barriers to use


1002 – Clinical staff pharmacists’ experience and awareness surrounding continuous prostacyclin therapies in pediatric pulmonary hypertension

Therapeutic Strategies

1003 – Pulmonary arterial hypertension (PAH) unit-based education program


1004 – The PERSIST study: A phase IV qualitative research analysis evaluating practices associated with high PAH medication persistence rates

1005 – Building sustained PH expertise in bedside nurses

Clinical Science

Databases and Registries

1007 – Clinical course of patients transitioned from another prostacyclin pathway agent (PPA) to selexipag in SPHERE

1008 – Frequency of palliative care referrals in newly diagnosed pulmonary arterial hypertension (PAH): The Pulmonary Hypertension Association Registry

1009 – Risk assessment at baseline and one year in patients with pulmonary Arterial Hypertension (PAH): Data from the first 250 patients enrolled in SPHERE (Uptravi® [SelexiPag]: tHe UsErs dRug rEgistry)

1010 – Clinical course of patients enrolled in SPHERE (SelexiPag: tHe UsErs dRug rEgistry), a U.S. pulmonary arterial hypertension (PAH) registry: One-year follow up

Diagnosis, Screening and Assessment

1011 – Clinical presentation and hemodynamics of adults with Eisenmenger syndrome and idiopathic pulmonary hypertension

1012 – Implementation of genetic counseling and genetic testing in a Pulmonary Hypertension Comprehensive Care Center

1013 – Pulmonary hypertension in ESRD: Pre-capillary, post-capillary or both? Examining hemodynamic profiles of an inner-city population via right heart catheterization

1014 – Self-Reported pulmonary hypertension (PH) referral trends amongst U.S.-based physicians

1015 – Awareness and diagnostic trends of pulmonary hypertension (PH) amongst U.S.-based physicians

1016 – Risk assessment in functional class (FC) II pulmonary arterial hypertension (PAH) patients: comparison of physician gestalt with ESC/ERS-guidelines and REVEAL 2.0


1017 – Cardiac MR derived septal curvature is correlated with clinical outcomes in bronchopulmonary dysplasia associated pulmonary hypertension

Quality of Life

1018 – Feasibility of utilizing one-day vs. seven-day results of the pulmonary arterial hypertension (PAH)-SYMPACT tool

1019 – Nurse staffing and the quality of life and outcomes of patients with pulmonary arterial hypertension: The Pulmonary Hypertension Association Registry

1020 – Acceptance of a multi-component complementary health approach for symptom management: Qualitative analysis from persons living with pulmonary hypertension

Therapeutic Strategies

1021 – Challenges and evolution of prostanoid therapies in the Middle East: Insights from UAE PH database

1022 – Pulmonary hypertension in end stage renal disease: An examination of hemodynamic responses following the inhaled vasodilator challenge

1023 – Role transition within a pulmonary hypertension model of care

1024 – Titration regimen of continuous intravenous sildenafil in neonates and children with pulmonary hypertension: A single center experience

1025 – Anticoagulation in pulmonary arterial hypertension: A decision analysis


1026 – A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of Treprostinil Inhalation Powder (TreT) in healthy normal volunteers

1027 – An open-label, clinical study to evaluate the safety and tolerability of Treprostinil Inhalation Powder (TreT) in patients with pulmonary arterial hypertension (BREEZE Study)

1028 – Clinical evaluation of patients with pulmonary arterial hypertension transitioned from the combination of bosentan and sildenafil to alternative therapy

1029 – Converting from brand to generic treprostinil (intravenous): Aggregate cohort data from one specialty pharmacy

1030 – Evaluation of safety and efficacy of rapid-titration treprostinil at a large community hospital

1031 – Preclinical and clinical pharmacokinetics of L606, An extended-release formulation of treprostinil for inhalation therapy

1032 – The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)

1033 – Treatment patterns and medication adherence and persistence among patients with pulmonary arterial hypertension in real-world database representing a large U.S. health plan

1034 – Treatment with oral treprostinil delays disease progression in participants with pulmonary arterial hypertension: Results from the FREEDOM-EV Study

1035 – Safety and efficacy of moderate to high intensity aerobic exercise and strength training in pulmonary hypertension (PH): A pilot study

1036 – A real-world multidisciplinary approach to successful patient adherence and maintenance on oral selexipag therapy

1037 – Value of baseline cardiac magnetic resonance imaging for predicting adverse outcomes in treatment-naïve pulmonary hypertension patients

Case Studies

Associated Diseases and Conditions

1038 – Reversible pre-capillary pulmonary hypertension in a patient with systemic AL amyloidosis: A rare association and outcome

1039 – Treatment of Epstein’s Anomaly related exercise-induced pulmonary hypertension: A case report

1040 – Severe hemolysis in patient with known G6PD deficiency treated with macitentan and riociguat

Databases and Registries

1041 – Preparation for a Pulmonary Hypertension (PH) Care Center accreditation visit at a community pulmonary hypertension program

Mechanistic Studies

1042 – Engaging PAH patients in the drug development process


1043 – Hank the Heart gets PH! Character storytelling animations as a new digital media tool to educate and engage patients and families with pulmonary hypertension

Quality of Life

1044 – Compassionate use of inhaled treprostinil in acute right heart failure due to CTEPH

Therapeutic Strategies

1045 – Rapid transition from oral selexipag to subcutaneous treprostinil in pulmonary arterial hypertension

1046 – Tamponade without the tamponade: A case of severe decompensated pulmonary hypertension

1047 – Evaluation of a pharmacist discharge counseling process in pulmonary hypertension patients

1048 – Pulmonary arterial hypertension emergency complications and evaluation: Practical guide for the advanced practice registered nurses in the emergency department


1049 – Describing the transition from parenteral treprostinil to oral treprostinil or selexipag in patients with pulmonary arterial hypertension: Case series

1050 – Going rogue: Forgoing riociguat for inhaled treprostinil in a patient with CTEPH and sickle cell disease

1051 – Transitions between intravenous (IV) or subcutaneous (SQ) and oral prostacyclin pathway agents (PPAs) in pulmonary arterial hypertension (PAH): Four case reports

1052 – A successful case of PAH management through pregnancy and delivery

1053 – Use of selexipag for pulmonary hypertension in a patient with durable LVAD: Is there a role for outpatient prostacyclin analogues in patients with LVAD and pulmonary hypertension?

1054 – It takes a village: Treatment success with subcutaneous treprostinil in adult patient with Trisomy 21 and severe pulmonary arterial hypertension